Rachit Kumar

Rachit Kumar

Auto-generated profile, based on publicly available information

Rachit Kumar

Department of Radiation Oncology, MD Anderson Cancer Center, Houston, TX; Department of Radiation Oncology, Banner MD Anderson Cancer Center, Gilbert, AZ

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Brachytherapy
Verified
Journal Article
Closed access
LALauren Andring
Lauren Andring
AYAlison Yoder
Alison Yoder
TPTodd Pezzi
Todd Pezzi
CTChad Tang
Chad Tang
RKRachit Kumar
Rachit Kumar
GWGary V. Walker
Gary V. Walker

5 February 2019 in JMIR Research Protocols
Verified
Journal Article
Open access
AAAmit Algotar
Amit Algotar
CHChiu-Hsieh Hsu
Chiu-Hsieh Hsu
HCH.-H. Sherry Chow
H.-H. Sherry Chow
SDShona Dougherty
Shona Dougherty
HMHani Babiker, MD
Hani Babiker, MD
CTCynthia Thomson
Cynthia Thomson
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet #Preprint #PeerReviewMe: Warning: This is a unreviewed preprint. Readers are warned that the document has not been peer-reviewed by expert/patient reviewers or an academic editor, may contain misleading claims, and is likely to undergo changes before final publication, if accepted, or may have been rejected/withdrawn. Readers with interest and expertise are encouraged to sign up as peer-reviewer, if the paper is within an open peer-review period. Please cite this preprint only for review purposes or for grant applications and CVs (if you are the author). Background: Androgen deprivation therapy (ADT) for prostate cancer (PCa) is associated with adverse cardio-metabolic effects such as reduced libido, hot flashes, metabolic syndrome, diabetes, myocardial infarction and stroke. This reduces quality of life (QoL) and potentially increases mortality. Several large clinical trials have demonstrated improvements in cardio-metabolic risk with comprehensive multi-modality lifestyle modification. However, there is paucity of data for such interventions in men on ADT for PCa and existing studies have used non-standardized interventions or lacked data on metabolic risk factors. Objective: Aim of the Comprehensive Lifestyle Improvement Project for Prostate Cancer (CLIPP), is designed to address these gaps by using an intervention modeled after The Diabetes Prevention Program (DPP), a standardized multi-component intervention with demonstrated effectiveness in reducing cardio-metabolic risk factors that has been successfully adapted for multiple disease types including breast cancer. Methods: A single-arm unblinded clinical trial will be conducted to determine the feasibility of conducting a 24-week comprehensive lifestyle modification intervention (CLMI) that targets weight loss and increased physical activity modeled on the DPP in 30 men on ADT for PCa. Secondary aims are to determine the effect of CLMI on cardio-metabolic markers and QoL. The tertiary aim is to determine the effect of CLMI on markers of inflammation and angiogenesis, important mechanisms for PCa progression. Participants will be recruited from the University of Arizona Cancer Center and the surrounding community. The intervention will be delivered weekly in-person and over the telephone for 16 weeks. For weeks 16 through 24, participants receive weekly phone calls from the study health coach to motivate them to continue their CLMI. Questionnaire and biological data are collected at baseline, 12 and 24 weeks. Body composition using Dual-energy x-ray absorptiometry (DXA) scans will be performed at baseline and end of study. Results: Based on a sample size of 30, the two-sided 95% confidence interval will not be wider than 0.373 standard deviations for the adherence rate and will not be wider than 0.374 for the retention rate. In addition, the study will have a power of 80% to detect a change of 0.47 standard deviations from baseline for each of the markers investigated in the secondary and tertiary aims assuming a within-subject correlation of 0.20 at a significance level of 5%. Recruitment has recently started and is expected to be completed in 6 months. Conclusions: The CLIPP study determines the feasibility of conducting a DPP style CLMI in men with ADT for PCa and its effects on cardio-metabolic adverse effects, QoL as well as markers of inflammation and angiogenesis. Results will inform the development of future clinical trials in this population. Clinical Trial: Clinicaltrials.gov, pending

31 December 2017
Verified
Book Chapter
Closed access
PDF file
RKRachit Kumar
Rachit Kumar
GWGary Walker
Gary Walker
LRLauren Rosati
Lauren Rosati
SNSweet Ping Ng
Sweet Ping Ng
JHJoseph M. Herman
Joseph M. Herman

22 October 2018 in JMIR Preprints
Verified
Preprint
Open access
AAAmit Algotar
Amit Algotar
CHChiu-Hsieh Hsu
Chiu-Hsieh Hsu
HCH.-H. Sherry Chow
H.-H. Sherry Chow
SDShona Dougherty
Shona Dougherty
HMHani Babiker, MD
Hani Babiker, MD
CTCynthia Thomson
Cynthia Thomson
BACKGROUND Androgen deprivation therapy (ADT) for prostate cancer is associated with adverse cardiometabolic effects such as reduced libido, hot flashes, metabolic syndrome, diabetes, myocardial infarction, and stroke. This reduces quality of life and potentially increases mortality. Several large clinical trials have demonstrated improvements in cardiometabolic risk with comprehensive multimodality lifestyle modification. However, there is a lack of data for such interventions in men on ADT for prostate cancer, and existing studies have used non-standardized interventions or lacked data on metabolic risk factors. OBJECTIVE The Comprehensive Lifestyle Improvement Project for Prostate Cancer (CLIPP) is designed to address these gaps by using an intervention modeled on the Diabetes Prevention Program, a standardized multicomponent intervention with demonstrated effectiveness in reducing cardiometabolic risk factors that has been successfully adapted for multiple disease types including breast cancer. METHODS A single-arm unblinded clinical trial will be conducted to determine the feasibility of conducting a 24-week comprehensive lifestyle modification intervention that targets weight loss and increased physical activity modeled on the Diabetes Prevention Program in 30 men on ADT for prostate cancer. Secondary aims are to determine the effect of the intervention on cardiometabolic markers and quality of life. The tertiary aim is to determine the effect of the intervention on markers of inflammation and angiogenesis, important mechanisms for prostate cancer progression. Participants will be recruited from the University of Arizona Cancer Center and the surrounding community. The intervention will be delivered weekly in person and over the phone for 16 weeks. For Weeks 16-24, participants receive weekly phone calls from the study health coach to motivate them to continue their lifestyle modification. Questionnaire and biological data are collected at baseline, 12 weeks, and 24 weeks. Body composition using dual-energy x-ray absorptiometry scans will be performed at baseline and end of study. RESULTS Based on a sample size of 30, the two-sided 95% confidence interval will not be wider than 0.373 standard deviations for the adherence rate and will not be wider than 0.374 for the retention rate. In addition, the study will have a power of 80% to detect a change of 0.47 standard deviations from baseline for each of the markers investigated in the secondary and tertiary aims assuming a within-subject correlation of 0.20 at a significance level of 5%. The recruitment period is from October 2018 to April 2019. CONCLUSIONS The aim of CLIPP is to determine the feasibility of conducting a Diabetes Prevention Program–style comprehensive lifestyle modification intervention in men with ADT for prostate cancer and its effects on cardiometabolic adverse effects, quality of life, as well as markers of inflammation and angiogenesis. Results will inform the development of future clinical trials in this population. INTERNATIONAL REGISTERED REPOR DERR1-10.2196/12579